x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230093
| Product Information | |
|---|---|
| CAS No. | 1134156-31-2 |
| Synonyms | adenosine-derived inhibitor, VER155008, VER-155008, me 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile |
| Formula | C25H23Cl2N7O4 |
| Molecular Weight | 556.4 |
| Product Description | VER-155002 is a small molecule, ATP-derivative inhibitor of HSP70 (IC50 = 500 nM). The compound inhibits proliferation of several colon and breast cancer cell lines, induces caspase dependent apoptosis in BT474 cells and down regulates expression of Her2 and Raf-1 in HCT116 cells. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 98% |
| Shipping | Shipped at room temperature. |
| Storage | Store at or below –20 °C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day. |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
